Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives of DAF and CureLeads, in the presence of Eng. Hatem Kandil, CEO and Managing Director of DAF, and Dr. Mohamed Rammal, Director of CureLeads.
The meeting aimed to explore mechanisms for strengthening cooperation in the field of innovative therapies, as well as to review procedures for importing these medicines and making them available in the Egyptian market in accordance with approved regulatory standards.
During the meeting, Dr. Ali El-Ghamrawy underscored the Authority’s commitment to supporting the entry of innovative pharmaceutical treatments into the Egyptian market, noting that facilitating procedures remains one of the Authority’s key priorities, without compromising quality and efficacy standards.
He explained that the EDA is working to provide a regulatory environment that encourages innovation and scientific research, enabling global companies to introduce the latest treatments to Egyptian patients safely and efficiently, while maintaining the highest levels of quality and safety.
He emphasized the importance of strengthening cooperation with reputable companies and overcoming regulatory challenges in a way that supports pharmaceutical security, ensures patients’ access to the latest treatments, and reinforces international confidence in the Egyptian regulatory system.
For their part, CureLeads representatives delivered a detailed presentation on the scientific and technical aspects of their pharmaceutical products. Discussions also addressed ways to expedite market access procedures through various regulatory pathways, ensuring that products are made available with the highest standards of quality and effectiveness.
Representatives of CureLeads and DAF expressed their appreciation for the efforts exerted by the Egyptian Drug Authority to support the entry of innovative medicines into the local market. They affirmed that the clear and streamlined regulatory procedures offered by the Authority provide an attractive environment for investment and innovation, and help ensure that patients gain access to advanced treatments with the highest standards of safety and quality.
Attending the meeting on behalf of the Egyptian Drug Authority was Dr. Osama Hatem, Associate to the EDA Chairman for Policy and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access. Participating from CureLeads was Dr. Baher Mohamed, Medical Director, and from DAF, Dr. Engy Alaa, Marketing Director.
The meeting comes within the framework of the Egyptian Drug Authority’s ongoing efforts to strengthen international partnerships, encourage global companies to invest in the Egyptian market, and support the availability of innovative therapies that meet patient needs and enhance the healthcare system.